<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN"
       "https://jats.nlm.nih.gov/publishing/1.3/JATS-journalpublishing1-3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" dtd-version="1.3" article-type="research-article" xml:lang="en">
 <front>
  <journal-meta>
   <journal-id journal-id-type="nlm-ta">Ulutas Med J</journal-id>
   <journal-title-group>
    <journal-title>The Ulutas Medical Journal</journal-title>
    <abbrev-journal-title>Ulutas Med J</abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="ppub">2149-0430</issn>
   <issn pub-type="epub">2149-388X</issn>
   <publisher>
    <publisher-name>Hayriye Zehra Ulutaş</publisher-name>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="doi">10.5455/umj.20211220121456</article-id>
   <article-id pub-id-type="publisher-id">88290</article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>Original Article</subject>
    </subj-group>
    <subj-group subj-group-type="subject">
     <subject>Otorhinolaryngology</subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title>Evaluation of Nasociliary Clearance in Covid-19 Patients</article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author">
     <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6276-8355</contrib-id>
     <name name-style="western">
      <surname>Ayral</surname>
      <given-names>Muhammed</given-names>
     </name>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
     <xref ref-type="aff" rid="aff1">1</xref>
    </contrib>
    <contrib contrib-type="author" corresp="yes">
     <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2421-4842</contrib-id>
     <name name-style="western">
      <surname>Dedeoglu</surname>
      <given-names>Serkan</given-names>
     </name>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
     <xref ref-type="aff" rid="aff2">2</xref>
    </contrib>
    <contrib contrib-type="author">
     <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3879-8794</contrib-id>
     <name name-style="western">
      <surname>Toprak</surname>
      <given-names>Serdar Ferit</given-names>
     </name>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
     <xref ref-type="aff" rid="aff1">1</xref>
    </contrib>
    <aff id="aff1">
     <label>1</label>
     <institution-wrap>
      <institution-id institution-id-type="ror">https://ror.org/0257dtg16</institution-id>
      <institution>Department of Otorhinolaryngology, Dicle University, Faculty of Medicine, Diyarbakır, Turkey</institution>
     </institution-wrap>
    </aff>
    <aff id="aff2">
     <label>2</label>
     <institution-wrap>
      <institution-id institution-id-type="ror">https://ror.org/03f2jcq85</institution-id>
      <institution>Department of Otorhinolaryngology, Yaşargil Training and Research Hospital, Diyarbakır, Turkey</institution>
     </institution-wrap>
    </aff>
   </contrib-group>
   <pub-date publication-format="electronic" date-type="pub" iso-8601-date="2022-03-09">
    <day>09</day>
    <month>03</month>
    <year>2022</year>
   </pub-date>
   <pub-date publication-format="print" date-type="collection">
    <year>2022</year>
   </pub-date>
   <volume>8</volume>
   <issue>1</issue>
   <fpage>45</fpage>
   <lpage>50</lpage>
   <history>
    <date date-type="received" iso-8601-date="2021-12-20">
     <day>20</day>
     <month>12</month>
     <year>2021</year>
    </date>
    <date date-type="rev-recd" iso-8601-date="2022-01-03">
     <day>03</day>
     <month>01</month>
     <year>2022</year>
    </date>
    <date date-type="accepted" iso-8601-date="2022-01-18">
     <day>18</day>
     <month>01</month>
     <year>2022</year>
    </date>
   </history>
   <permissions>
    <copyright-statement>© 2022 The Author(s)</copyright-statement>
    <copyright-year>2022</copyright-year>
    <license>
     <ali:license_ref>https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
     <license-p>This is an open access article distributed under the CC BY-NC 4.0 licence.</license-p>
    </license>
   </permissions>
   <self-uri xlink:href="https://www.ulutasmedicaljournal.com/?mno=88290"/>
   <self-uri content-type="pdf" xlink:href="https://www.ulutasmedicaljournal.com/pdf/88290.pdf"/>
   <abstract>
    <p>Introduction: The new coronavirus 2019 (COVID-19), which rapidly turned into a global pandemic, progresses with mild flu-like symptoms, suggesting that there may be damage to the nasociliary clearance. The study aimed to evaluate whether nasociliary clearance in individuals with Covid-19 is affected or not using the saccharin test. Materials and Methods: Saccharin test was applied to 47 PCR positive active COVID-19, 42 recovered PCR negative COVID-19, and 42 healthy groups to evaluate their nasociliary functions and the result was calculated in minutes. Results: 42 (32.1%) recovered patients, 42 (32.1%) healthy, and 47 (35.9%) COVID-19 patients were included in the study. There were 13 women (31%), 29 men (69%) in the healthy, 18 women (42.9%), 24 men (57%) in the recovered group, 14 women (29.8%), and 33 men (70%) in the active patients. The mean times of saccharin nasociliary clearance were 24 (18-27) min in the active covid-19 patient group, 13 (8-17) min in the recovered covid-19 group, and 11 (8-13) min in the healthy. There was a difference between the groups in terms of the Saccharine test (p&lt;0.001). Discussion: We observed that COVID-19 patients showed a negative effect on nasociliary clearance time in the early period, similar to viral infections that cause other upper respiratory tract infections. We detected rapid healing in nasociliary clearance after the COVID-19 disease effect wore off.</p>
   </abstract>
   <kwd-group kwd-group-type="author">
    <kwd>COVID-19</kwd>
    <kwd>nasal provocation tests</kwd>
    <kwd>Saccharin</kwd>
    <kwd>Smell</kwd>
    <kwd>Upper respiratory tract infections</kwd>
   </kwd-group>
   <funding-group>
    <funding-statement>Conflict of Interest The authors declare no conflict of interest and financial support.</funding-statement>
   </funding-group>
  </article-meta>
 </front>
 <body>
  <sec id="sec-1">
   <title>Introduction</title>
   <p id="b-1">The new coronavirus disease 2019 (COVID-19), which emerged in Wuhan, a city of China's Hubei province in December 2019 and rapidly transformed into a global pandemic, shows a deadly course as well an asymptomatic course (    <xref ref-type="bibr" rid="ref1">1</xref>
). The most common ways of transmission are shown as human-to-human respiratory droplet and direct contact transmission, but also the fecal-oral transmission, fomite transmission (by object), and perinatal (intrauterine) transmission are observed (    <xref ref-type="bibr" rid="ref1">1</xref>
–    <xref ref-type="bibr" rid="ref3">3</xref>
).</p>
   <p id="b-2">The most common symptoms in the disease, which have a wide clinic from asymptomatic or mild symptoms to severe dyspnea, are dry cough, fever, and fatigue (    <xref ref-type="bibr" rid="ref3">3</xref>
). In some cases, loss of taste, diarrhea and smell were seen (    <xref ref-type="bibr" rid="ref4">4</xref>
). According to the studies conducted in China, almost 80% of the cases overcome the disease with mild symptoms, severe symptoms develop in 15%, and intensive care is required in 5% of cases (    <xref ref-type="bibr" rid="ref4">4</xref>
,    <xref ref-type="bibr" rid="ref5">5</xref>
). The definitive diagnosis is made by applying PCR (polymerase chain reaction) test to the swab taken from nasopharynx (    <xref ref-type="bibr" rid="ref3">3</xref>
). The upper and lower respiratory tracts have developed a very effective defense system to protect themselves against pathogens, toxins, and particle matter (    <xref ref-type="bibr" rid="ref6">6</xref>
). Mucociliary clearance is the primary defense mechanism of the upper and lower respiratory tracts. Acquired or hereditary impairment of this process can cause some serious respiratory infections (    <xref ref-type="bibr" rid="ref7">7</xref>
,    <xref ref-type="bibr" rid="ref8">8</xref>
). Mucociliary clearance, measured as the inhaled aerosol elimination time, serves as one of the cornerstones of this defense and is used to evaluate the combined effect of the mucosa-ciliary system (    <xref ref-type="bibr" rid="ref8">8</xref>
). Since it does not require topical anesthesia, is non-invasive, low cost, inexpensive, reliable, and easy to apply, the most preferred method to evaluate mucociliary clearance is the saccharin test (    <xref ref-type="bibr" rid="ref6">6</xref>
,    <xref ref-type="bibr" rid="ref7">7</xref>
,    <xref ref-type="bibr" rid="ref9">9</xref>
–    <xref ref-type="bibr" rid="ref11">11</xref>
).</p>
   <p id="b-3">The coronavirus that causes COVID-19 disease can extend mucociliary clearance time and increase nasal resistance. This study aimed to evaluate the nasal mucociliary clearance time (NMCC) with the saccharin test in COVID-19.</p>
  </sec>
  <sec id="sec-2">
   <title>Materials and Methods</title>
  </sec>
  <sec id="sec-3">
   <title>Ethical Statement</title>
   <p id="b-4">Ethics committee approval was received from the Dicle University clinical research ethics committee (meeting date 26.11.2020 number 07). Informed consent was obtained from all participants who participated in the study. This prospective study was conducted on 47 active covid-19 patients who were admitted to the Dicle University Pandemic Hospital flu policlinic between October and December 2020, who were diagnosed with RT-PCR positivity without taste and odor    <sub>-</sub>
related symptoms, 42 recovered Covid-19 groups who had two consecutive negative real-time RT-PCR tests at least with 24- hour intervals and who do no longer need isolation in the absence of relevant clinical or epidemiological criteria, and 42 healthy group. Nurses, physicians and healthcare professionals who were healthy, well-fed, without a history of smoking, working at similar room temperatures and relative humidity, and in the similar environment, who agreed to be part of the study were includedin the study. We performed the saccharine test for all hospitalized patients suspected of COVID-19 on day 1 of their hospitalization before receiving any treatment.</p>
   <sec id="sec-4">
    <title>Exclusion Criteria</title>
    <p id="b-5">Patients younger than 18 years and older than 45 years, patients with complaints about smell and taste in COVID-19 infection, patients with nasal surgery history, patients with a previous history of smell and taste dysfunction, smokers, individuals with nasal polyp and allergic rhinitis have been excluded. The saccharin test was performed by the only rhinolaryngologist experienced in this field, wearing protective clothing, glasses, visor, and an N95 mask. While the patient was sitting in an upright position, a saccharine (1/4 saccharine tb) of approximately 1 mm in diameter was placed on the medial side of the inferior turbinate using bayonet forceps. Patients were instructed not to snuffle, to try to clear their nose, or to sneeze during the test. The total time (in minutes) from saccharine administration to the first sweet taste sensation is measure of mucociliary clearance. Transport time longer than twenty minutes indicates impaired mucociliary transport. The average saccharine time varies between 7 - 15 minutes. Values of time longer than 20 minutes were considered pathological in our study (     <xref ref-type="bibr" rid="ref12">12</xref>
). If the patient did not taste any sweetness after 20 minutes, an additional saccharin particle was placed in the anterior part of the subject's tongue to exclude loss of taste. In addition, patients with affected taste and odor levels were excluded from the study because they may affect the saccharin test.</p>
   </sec>
   <sec id="sec-5">
    <title>Statistical Analysis</title>
    <p id="b-6">Analyzes were evaluated in the SPSS (Statistical Package for Social Sciences; SPSS Inc. Chicago, IL) 22 package programs. Descriptive data in the study were shown as n, % values in categorical data, and as median, interquartile range (25-75 percentile values) values in continuous data. Chi-square analysis (Pearson Chi-square) was used to compare categorical variables between groups. The suitability of continuous variables to normal distribution was evaluated with the Kolmogorov- Smirnov Test. Since continuous variables were seen to be incompatible with normal distribution, the Kruskal Wallis test was used for comparison between more than two groups. The statistical significance level in the analysis was accepted as p&lt;0.05.</p>
   </sec>
  </sec>
  <sec id="sec-6">
   <title>Results</title>
   <p id="b-7">47(35.9%) COVID-19, 42(32.1%) healed Covid- 19 patients, and 42 (32.1%) healthy individuals were included. There were 13 women (31%), 29 men (69%) in the healthy, 18 women (42.9%), 24 men (57%) in the recovered, 14 women (29.8%), and 33 men (70%) in the active patient group. No difference was found in terms of gender (p=0.368). The mean age of the healthy group was 30 (25-34) years, the mean age of the recovered group was 31.5 (29-36) years, and the mean age of the active patients' group was 34 (29-36) years. No significant difference was observed in terms of age (p=0.119).</p>
   <fig id="fig-1" position="float">
    <label>Figure 1</label>
    <caption>
     <p>Group results according to the saccharine test</p>
    </caption>
    <graphic xlink:href="fig-1.png">
     <alt-text>Figure 1: Group results according to the saccharine test</alt-text>
    </graphic>
   </fig>
   <p id="b-8">There was a difference between the groups in terms of the Saccharine test (p&lt;0.001). The difference was due to the difference between the patient and the healthy group, and the patient and the recovered (Table-1, Figure-1). No significance was determined between the recovered covid-19 and the healthy group.</p>
  </sec>
  <sec id="sec-7">
   <title>Discussion</title>
   <p id="b-9">The function of the mucus and ciliary system can be assessed by mucociliary clearance (    <xref ref-type="bibr" rid="ref13">13</xref>
). Mucociliary clearance is the most important defense mechanism of the nasal respiratory epithelium, which plays a key role in the defense mechanism of the upper and lower respiratory tracts (    <xref ref-type="bibr" rid="ref14">14</xref>
). Mucociliary clearance is the measurement of the elimination of inhaled aerosols (    <xref ref-type="bibr" rid="ref15">15</xref>
). Effective mucociliary clearance requires proper functioning of cilia and adequate mucus quantity. The abnormal ciliary function can cause chronic sepsis of the upper and lower respiratory tracts, and this has been reported to cause severe respiratory tract infections in susceptible individuals (    <xref ref-type="bibr" rid="ref9">9</xref>
,    <xref ref-type="bibr" rid="ref13">13</xref>
). Potentially harmful substances are kept in this mucus layer and are removed from the nasal cavity towards the nasopharynx by the movements of the cilia (    <xref ref-type="bibr" rid="ref8">8</xref>
,    <xref ref-type="bibr" rid="ref13">13</xref>
). Acute upper respiratory tract infections are known to disrupt the structure of ciliary cells and cause a deficiency in clearance. The incidence and variability of abnormal hair may be related to the severity and duration of clinical symptoms such as cough and rhinorrhea (    <xref ref-type="bibr" rid="ref16">16</xref>
,    <xref ref-type="bibr" rid="ref17">17</xref>
).</p>
   <p id="b-10">The most common method for measuring mucociliary clearance is the saccharin test because it is practical, easy, and low cost (    <xref ref-type="bibr" rid="ref8">8</xref>
,    <xref ref-type="bibr" rid="ref17">17</xref>
). Fever, cough, fatigue, and muscle pain are often the main symptoms of COVID-19 patients. Nasal congestion, headache, nasal flow, sore throat, vomiting, and diarrhea are considered as fewer common symptoms (    <xref ref-type="bibr" rid="ref18">18</xref>
–    <xref ref-type="bibr" rid="ref23">23</xref>
). In Europe, younger patients applied with symptoms related to otolaryngology more often than older patients (    <xref ref-type="bibr" rid="ref24">24</xref>
). European patients had a higher rate of odor-related disorders than Asian patients (    <xref ref-type="bibr" rid="ref24">24</xref>
,    <xref ref-type="bibr" rid="ref25">25</xref>
). It has been suggested that olfactory dysfunction in COVID-19 infection may be associated with the involvement of the olfactory bulb or peripheral damage of olfactory receptor cells in the nasal neuro-epithelium (    <xref ref-type="bibr" rid="ref26">26</xref>
). It has been proposed that this may be more common in European due to higher ACE2 expression in the nasal mucosa (    <xref ref-type="bibr" rid="ref24">24</xref>
–    <xref ref-type="bibr" rid="ref26">26</xref>
). The elderly can have an irreversible course with sepsis, respiratory failure, heart failure, and septic shock when they present underlying chronic diseases such as heart disease and diabetes (    <xref ref-type="bibr" rid="ref27">27</xref>
,    <xref ref-type="bibr" rid="ref28">28</xref>
). Cardiac disease and diabetes have been found to increase the risk of death twice more than other risk factors (    <xref ref-type="bibr" rid="ref27">27</xref>
). Patients with mild to moderate symptoms have the opportunity to manage symptoms at home without the need for hospitalization, while patients with severe features should be followed up in intensive care units (    <xref ref-type="bibr" rid="ref19">19</xref>
–    <xref ref-type="bibr" rid="ref21">21</xref>
).</p>
   <table-wrap id="tbl-1" position="float">
    <label>Table 1</label>
    <caption>
     <title>Comparisons by demographic values and tests</title>
    </caption>
    <graphic xlink:href="tbl-1.png">
     <alt-text>Table 1: Comparisons by demographic values and tests</alt-text>
    </graphic>
   </table-wrap>
   <p id="b-11">The damage caused by COVID-19 on the nasal mucosa is not known. In a study performed using the Nasal Schirmer test, no significant difference was found between the control group and COVID-19 patients in terms of nasal secretion. It states that anosmia is not affected by nasal mucosal secretions (    <xref ref-type="bibr" rid="ref29">29</xref>
). We did not find any study evaluating nasociliary clearance in the literature. In this study, we evaluated the active patient group with COVID-19 infection who did not have any complaints about odor and taste, the patient group who had COVID- 19 and were accepted as recovered, and the healthy control group in terms of nasociliary clearance with the saccharin test.</p>
   <p id="b-12">In our study, we found a significant difference between the active COVID-19 patient and the recovered patient group, and the control group. No significant difference was observed between the recovered patient group and the healthy control group. In this study, we showed that COVID-19 disease shows a negative effect on nasociliary clearance and that nasociliary clearance has improved over time.</p>
   <p id="b-13">The limitation of our study was the fact that the saccharin test was performed on the day the patient was hospitalized for active patients. If it could be done on the days when the first symptoms started, it could provide us with more accurate data. In addition, the fact that we have a small ill patient group is considered a limitation of our study. We believe that studies evaluating more cases and earlier nasociliary clearance will be useful.</p>
  </sec>
  <sec id="sec-8">
   <title>Conclusions</title>
   <p id="b-14">COVID-19 patients showed a negative effect on nasociliary clearance time in the early period, similar to viral infections that cause other upper respiratory tract infections and we detected rapid healing in nasociliary clearance after COVID-19 effect wore off. More studies are needed to clarify the pathogenesis of the disorder in nasal mucosa of COVID-19.</p>
  </sec>
 </body>
 <back>
  <ref-list>
   <title>References</title>
   <ref id="ref1">
    <label>1</label>
    <mixed-citation publication-type="journal">Meng L, Hua F, Bian ZJJodr. Coronavirus disease 2019 (COVID-19): emerging and future challenges for dental and oral medicine. 2020;99(5):481-487</mixed-citation>
   </ref>
   <ref id="ref2">
    <label>2</label>
    <mixed-citation publication-type="journal">Chan KW, Wong VT, Tang SCWJTAjoCm. COVID-19: An update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese– Western medicine for the management of 2019 novel coronavirus disease. 2020;48(03):737-762</mixed-citation>
   </ref>
   <ref id="ref3">
    <label>3</label>
    <mixed-citation publication-type="journal">Zhou D, Zhang P, Bao C, Zhang Y, Zhu N. Emerging understanding of etiology and epidemiology of the novel coronavirus (COVID19) infection in Wuhan, China.</mixed-citation>
   </ref>
   <ref id="ref4">
    <label>4</label>
    <mixed-citation publication-type="journal">Wu Z, McGoogan JJJ. of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. 2020</mixed-citation>
   </ref>
   <ref id="ref5">
    <label>5</label>
    <mixed-citation publication-type="journal">Grag K, Shubhanshu KJIJoO, Head, Surgery N. Effect of Covid-19 in Otorhinolaryngology Practice: A Review. 2020:1-4</mixed-citation>
   </ref>
   <ref id="ref6">
    <label>6</label>
    <mixed-citation publication-type="journal">Stannard W, O'Callaghan CJJoam. Ciliary function and the role of cilia in clearance. 2006;19(1):110-115</mixed-citation>
   </ref>
   <ref id="ref7">
    <label>7</label>
    <mixed-citation publication-type="journal">Mahmut D, Celil U, Evren O, Davut A, Suleyman GJEAO. Nasal mucociliary clearance in total laryngectomised patients. 2006; 263(12):1099-1104</mixed-citation>
   </ref>
   <ref id="ref8">
    <label>8</label>
    <mixed-citation publication-type="journal">Valía PP, Valero FC, Pardo JM, Rentero DB, Monte CGJAdB. Saccharin for the study of mucociliary clearance: reference values for a Spanish population. 2008;44(10):540-545</mixed-citation>
   </ref>
   <ref id="ref9">
    <label>9</label>
    <mixed-citation publication-type="journal">Sakakura Y, Ukai K, Majima Y, Murai S, Harada T, Miyoshi YJAo-l. Nasal mucociliary clearance under various conditions. 1983;96(1-2):167-173</mixed-citation>
   </ref>
   <ref id="ref10">
    <label>10</label>
    <mixed-citation publication-type="journal">Rusznak C, Devalia J, Lozewicz S, Davies RJRm. The assessment of nasal mucociliary clearance and the effect of drugs. 1994;88(2):89-101</mixed-citation>
   </ref>
   <ref id="ref11">
    <label>11</label>
    <mixed-citation publication-type="journal">Uslu H, Uslu C, Varoglu E, Demirci M, Seven BJIjocp. Effects of septoplasty and septal deviation on nasal mucociliary clearance. 2004;58(12):1108-1111</mixed-citation>
   </ref>
   <ref id="ref12">
    <label>12</label>
    <mixed-citation publication-type="journal">Greenstone M, Cole PJBjodotc. Ciliary function in health and disease. 1985;79:9-26</mixed-citation>
   </ref>
   <ref id="ref13">
    <label>13</label>
    <mixed-citation publication-type="journal">Lale A, Mason J, Jones NJCO. Mucociliary transport and its assessment: a review. 1998;23(5):388-396</mixed-citation>
   </ref>
   <ref id="ref14">
    <label>14</label>
    <mixed-citation publication-type="journal">Naxakis S, Athanasopoulos I, Vlastos IM, Giannakenas C, Vassilakos P, Goumas PJEaoo-r-l. Evaluation of nasal mucociliary clearance after medical or surgical treatment of chronic rhinosinusitis. 2009;266(9):1423-26</mixed-citation>
   </ref>
   <ref id="ref15">
    <label>15</label>
    <mixed-citation publication-type="journal">Cauwenberge PV, Ingels KJAo-l. Effects of viral and bacterial infection on nasal and sinus mucosa. 1996;116 (2):316-321</mixed-citation>
   </ref>
   <ref id="ref16">
    <label>16</label>
    <mixed-citation publication-type="journal">Carson JL, Collier AM, Hu S-CSJJour. Ultrastructural studies of hamster tracheal epithelium in vivo and in vitro. 1980;70(1):70-81</mixed-citation>
   </ref>
   <ref id="ref17">
    <label>17</label>
    <mixed-citation publication-type="journal">Sun S, Hsieh J, Tsai S, Ho Y, Kao CJNmc. The role of rhino scintigraphy in the evaluation of nasal mucociliary clearance function in patients with sinusitis. 2000;21(11): 1029-1032</mixed-citation>
   </ref>
   <ref id="ref18">
    <label>18</label>
    <mixed-citation publication-type="journal">Wu Y, Fan Z, Jin H. Assessment of bone metabolism in male patients with benign paroxysmal positional vertigo. Front Neurol 2018:9:742</mixed-citation>
   </ref>
   <ref id="ref19">
    <label>19</label>
    <mixed-citation publication-type="journal">Zu ZY, Jiang MD. Coronavirus disease 2019 (COVID-19): a perspective from China. 2020;296(2):E15-E25</mixed-citation>
   </ref>
   <ref id="ref20">
    <label>20</label>
    <mixed-citation publication-type="journal">Xu Z, Shi L, Wang YJLRM. Pathological findings of COVID-19 associated with acute respiratory distress syndrome, 2021</mixed-citation>
   </ref>
   <ref id="ref21">
    <label>21</label>
    <mixed-citation publication-type="journal">Guan W- j, Ni Z- y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. 2020;382(18): 1708-1720</mixed-citation>
   </ref>
   <ref id="ref22">
    <label>22</label>
    <mixed-citation publication-type="journal">Pascarella G, Strumia A, Piliego C, et al. COVID‐19 diagnosis and management: a comprehensive review. 2020;288(2):192-206</mixed-citation>
   </ref>
   <ref id="ref23">
    <label>23</label>
    <mixed-citation publication-type="journal">NaserGhandi A, Allameh SF, Saffarpour RJNm, infections n. All about COVID-19 in brief. 2020;35</mixed-citation>
   </ref>
   <ref id="ref24">
    <label>24</label>
    <mixed-citation publication-type="journal">Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus. 2020</mixed-citation>
   </ref>
   <ref id="ref25">
    <label>25</label>
    <mixed-citation publication-type="journal">Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Nature Publishing Group; 2020</mixed-citation>
   </ref>
   <ref id="ref26">
    <label>26</label>
    <mixed-citation publication-type="journal">Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R. Smell and taste dysfunction in patients with COVID-19: a systematic review and meta- analysis. Elsevier; 2020:1621-1631</mixed-citation>
   </ref>
   <ref id="ref27">
    <label>27</label>
    <mixed-citation publication-type="journal">Li B, Yang J, Zhao F, Zhi L, Wang X. Prevalencia e impacto de las enfermedades cardiovasculares y metabólicas en COVID-19 en China. 2020;109(10)</mixed-citation>
   </ref>
   <ref id="ref28">
    <label>28</label>
    <mixed-citation publication-type="journal">Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. 2020;395 (10229):1054-1062 50 77 Nasociliary Clearance in Covid-19 Ayral et al.</mixed-citation>
   </ref>
   <ref id="ref29">
    <label>29</label>
    <mixed-citation publication-type="journal">Islamoglu Y, Gemcioglu E, Ates IJIJoMS. Objective evaluation of the nasal mucosal secretion in COVID-19 patients with anosmia. 2020:1-3</mixed-citation>
   </ref>
  </ref-list>
 </back>
</article>
